The decision could open the door to greater generic competition, but its impact on treatment costs will depend on drug availability, pricing, and access to care
The decision could open the door to greater generic competition, but its impact on treatment costs will depend on drug availability, pricing, and access to care
<iframe src="https://hindustansphere.com/embed/cluster/f3c2d624e8014eb63b4efa5b0207a5ebeef09e7e" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Why India rejected a patent application for shorter drug-resistant TB treatment | Explained"></iframe>
The decision could open the door to greater generic competition, but its impact on treatment costs will depend on drug availability, pricing, and access to care
The decision could open the door to greater generic competition, but its impact on treatment costs will depend on drug availability, pricing, and access to care
